Ensuring an Open Channel with Regulatory and Medical Policy Opinion Leaders During COVID

Many companies, particularly new entrants into the U.S. pharma arena, are facing some level of disruption or impact on their projected timelines for seeking FDA licensure, gathering data from trials for filing, conducting health economics analyses needed to demonstrate improved outcomes, or conducting real-world evidence studies that can help inform medical societies’ deliberations on clinical […]

2020 and the luxury of limitations for clinical trials

COVID-19 has had a fundamental effect on every aspect of society, including clinical trials. The search for an effective vaccine or treatment for COVID-19 continues to move at record pace. However, many clinical trials in other therapeutic areas have either been delayed or essentially ground to a halt due to the pandemic. Such delays place […]

Unlocking virtual medical congresses

Medical congresses – crucial for the presentation of trial data, scientific exchange and the opportunity to engage with medical professionals, patient advocates, media and analysts – have been cancelled, postponed or are moving to virtual/part virtual.